Latest Content

Tirzepatide is now approved to lower cardiovascular death, heart attack, or stroke risk in adults with type 2 diabetes.

At a Chicago roundtable, clinicians detailed fragmented obesity and diabetes care, transplant-access barriers, and insurance-driven prescribing decisions.

FDA approves brepocitinib, the first oral, targeted therapy for adult dermatomyositis, backed by phase 3 VALOR data.

A 4-million-person study finds unvaccinated COVID-19 infection raises myocarditis, pericarditis, and death risk far more than the Pfizer vaccine.

Atlanta clinicians described obesity care that stalls between routine diagnosis and delayed treatment, with coverage rules driving therapy choices.

The findings reinforce monitoring and managing thrombotic risk across the PV population rather than focusing on traditionally defined high-risk patients.

Experts discussed childhood vaccine recommendations, school requirements, exemptions, misinformation, and vaccine hesitancy.

County-level CRC mortality fell substantially since 2000, but some counties still had rates more than 13 times the Healthy People 2030 target in 2019.

A poll finds awareness of the mifepristone abortion pill is rising, but safety doubts and legal battles persist.